49 GENES FOUND
Show / hide columns
XML |
RDF |
TSV |
Page
CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit Disease related genes Nucleoplasm Tissue enhanced
CACNA1B Calcium channel, voltage-dependent, N type, alpha 1B subunit Disease related genes Group enriched
CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C subunit Disease related genes Tissue enhanced
CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D subunit Cancer-related genes Nuclear membrane Mixed
CACNA1F Calcium channel, voltage-dependent, L type, alpha 1F subunit Disease related genes Mixed
CACNA1G Calcium channel, voltage-dependent, T type, alpha 1G subunit FDA approved drug targets Tissue enhanced
CACNA1H Calcium channel, voltage-dependent, T type, alpha 1H subunit Disease related genes Nucleoplasm Tissue enhanced
CACNA1I Calcium channel, voltage-dependent, T type, alpha 1I subunit FDA approved drug targets Tissue enhanced
CACNA1S Calcium channel, voltage-dependent, L type, alpha 1S subunit Disease related genes Tissue enriched
KCNA1 Potassium channel, voltage gated shaker related subfamily A, member 1 Disease related genes Tissue enriched
KCNA10 Potassium channel, voltage gated shaker related subfamily A, member 10 FDA approved drug targets Nucleoplasm Tissue enhanced
KCNA2 Potassium channel, voltage gated shaker related subfamily A, member 2 Disease related genes Tissue enriched
KCNA3 Potassium channel, voltage gated shaker related subfamily A, member 3 FDA approved drug targets Mixed
KCNA4 Potassium channel, voltage gated shaker related subfamily A, member 4 FDA approved drug targets Tissue enhanced
KCNA5 Potassium channel, voltage gated shaker related subfamily A, member 5 Disease related genes Tissue enhanced
KCNA6 Potassium voltage-gated channel subfamily A member 6 FDA approved drug targets Not detected
KCNA7 Potassium channel, voltage gated shaker related subfamily A, member 7 FDA approved drug targets Tissue enriched
KCNB1 Potassium channel, voltage gated Shab related subfamily B, member 1 Disease related genes Tissue enhanced
KCNB2 Potassium channel, voltage gated Shab related subfamily B, member 2 FDA approved drug targets Nucleoli Tissue enhanced
KCNC1 Potassium channel, voltage gated Shaw related subfamily C, member 1 Disease related genes Nucleus Tissue enriched
KCNC2 Potassium channel, voltage gated Shaw related subfamily C, member 2 FDA approved drug targets Plasma membrane Tissue enriched
KCNC3 Potassium channel, voltage gated Shaw related subfamily C, member 3 Disease related genes Tissue enhanced
KCND1 Potassium channel, voltage gated Shal related subfamily D, member 1 FDA approved drug targets Nucleus Mixed
KCND2 Potassium channel, voltage gated Shal related subfamily D, member 2 Disease related genes Tissue enhanced
KCND3 Potassium channel, voltage gated Shal related subfamily D, member 3 Disease related genes Mixed
KCNH2 Potassium channel, voltage gated eag related subfamily H, member 2 Disease related genes Tissue enhanced
KCNJ1 Potassium channel, inwardly rectifying subfamily J, member 1 Disease related genes Tissue enriched
KCNJ11 Potassium channel, inwardly rectifying subfamily J, member 11 Disease related genes Tissue enhanced
KCNJ12 Potassium channel, inwardly rectifying subfamily J, member 12 FDA approved drug targets Nucleoplasm Group enriched
KCNJ8 Potassium channel, inwardly rectifying subfamily J, member 8 Disease related genes Mixed
KCNK2 Potassium channel, two pore domain subfamily K, member 2 FDA approved drug targets Mitochondria Tissue enhanced
KCNK3 Potassium channel, two pore domain subfamily K, member 3 Disease related genes Tissue enhanced
KCNK9 Potassium channel, two pore domain subfamily K, member 9 Disease related genes Group enriched
KCNMA1 Potassium channel, calcium activated large conductance subfamily M alpha, member 1 Disease related genes Tissue enhanced
KCNN4 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4 Disease related genes Tissue enhanced
KCNQ1 Potassium channel, voltage gated KQT-like subfamily Q, member 1 Disease related genes Tissue enhanced
KCNQ2 Potassium channel, voltage gated KQT-like subfamily Q, member 2 Disease related genes Endoplasmic reticulum Tissue enriched
KCNQ3 Potassium channel, voltage gated KQT-like subfamily Q, member 3 Disease related genes Tissue enriched
SCN10A Sodium channel, voltage gated, type X alpha subunit Disease related genes Not detected
SCN11A Sodium channel, voltage gated, type XI alpha subunit Disease related genes Tissue enhanced
SCN1A Sodium channel, voltage gated, type I alpha subunit Disease related genes Nucleoplasm Tissue enhanced
SCN2A Sodium channel, voltage gated, type II alpha subunit Disease related genes Tissue enriched
SCN3A Sodium channel, voltage gated, type III alpha subunit FDA approved drug targets Tissue enriched
SCN4A Sodium channel, voltage gated, type IV alpha subunit Disease related genes Nucleoplasm Group enriched
SCN5A Sodium channel, voltage gated, type V alpha subunit Disease related genes Tissue enriched
SCN9A Sodium channel, voltage gated, type IX alpha subunit Disease related genes Plasma membrane Tissue enhanced
TRPA1 Transient receptor potential cation channel, subfamily A, member 1 Disease related genes Tissue enhanced
TRPM8 Transient receptor potential cation channel, subfamily M, member 8 FDA approved drug targets Tissue enriched
TRPV1 Transient receptor potential cation channel, subfamily V, member 1 FDA approved drug targets Mixed
Page
